New Approach to Stress Out Cancer Cells is Effective in Ovarian Cancer

May 26, 2020 10:00 am

Around 1,500 Australian women will be diagnosed with ovarian cancer this year, and one woman will die every eight hours from this disease.

High-grade serous ovarian cancer (HGSOC) is the most common form of ovarian cancer and accounts for 70%-80% … Read more

New OS Data With Olaparib Support ‘New Era’ for Ovarian Cancer

May 14, 2020 10:00 am

By Liam Davenport

Women with platinum-sensitive relapsed ovarian cancer and a BRCA mutation could see their survival extended by over a year by maintenance therapy with the PARP-inihibitor olaparib (Lynparza, AstraZeneca).

The new overall survival (OS) data come … Read more

KRAS May Predict Benefit of MEK Inhibitors in Some Ovarian Cancers

May 11, 2020 10:30 am

By Ian Ingram

For women with recurrent or persistent low-grade serous ovarian cancer (LGSOC), presence of a KRAS mutation appeared to predict benefit from binimetinib (Mektovi), a post-hoc analysis from the phase III MILO trial found.

Among women treated with … Read more

FDA Approves Lynparza/Avastin With Myriad Genetics CDx for Platinum-Sensitive Ovarian Cancer

May 11, 2020 10:00 am

NEW YORK – The US Food and Drug Administration has approved olaparib (AstraZeneca/Merck’s Lynparza) in combination with bevacizumab (Genentech’s Avastin) as a maintenance regimen for advanced ovarian cancer patients who have homologous recombination deficiency (HRD) and are responding to first-line … Read more

FDA Approves Combination of Lynparza and Avastin as Maintenance Treatment for Advanced Ovarian Cancer

May 8, 2020 10:00 am

By Beth Fand Incollingo

The Food and Drug Administration (FDA) has approved the combination of two targeted drugs, Lynparza (olaparib) and Avastin (bevacizumab), for patients with advanced ovarian cancer who have responded to initial treatment with platinum-based chemotherapy plus Avastin … Read more

FDA Approves Niraparib for Advanced Ovarian Cancer

April 29, 2020 10:00 am

By Hannah Slater

The FDA approved niraparib (Zejula) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.1

Efficacy for … Read more

Blood Test Helped Detect Cancer Before Symptoms, Study Finds

April 28, 2020 10:45 am

by Marilynn Marchione

For the first time, a blood test has been shown to help detect many types of cancer in a study of thousands of people with no history or symptoms of the disease.

The test is still experimental. … Read more

AACR 2020: Cell-Free DNA Liquid Biopsy May Provide an Early Detection Test for Patients With Suspected Cancer

April 28, 2020 10:30 am

By Jo Cavallo

The Circulating Cell-free Genome Atlas Study is a large multicenter, case-controlled, observational study of 15,254 participants, 56% with cancer and 44% without cancer, with longitudinal follow-up to support the development of a cell-free DNA (cfDNA) multicancer early … Read more

Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at the AACR 2020 Virtual Annual Meeting I

April 27, 2020 10:20 am

BOSTON–(BUSINESS WIRE)– Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced results from the ongoing investigator-initiated Phase 1 clinical study investigating VS-6766, its

Read more

STRO-002 Shows Encouraging Results in Phase I Trial in Treatment of Ovarian Cancer

April 27, 2020 10:15 am

By Peter Hofland, Ph.D

Updated interim data from an ongoing Phase I dose-escalation phase clinical study (NCT03748186) evaluating the folate receptor alpha (FRα) antibody-drug conjugate (ADC) STRO-002 (Sutro Biopharma) shows encouraging results.[1]

The trial was designed to study … Read more

MD Anderson, Ipsen Advance New Therapy With Potential Benefit for Underserved Lung and Ovarian Cancer Patients

April 26, 2020 10:30 am

In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development … Read more

Abclon Derives Clinical Materials for CAR-T Treatment of Ovarian Cancer

April 21, 2020 6:00 pm

By Shim Hyun-tai

Antibody-based therapeutics developer Abclon said Tuesday that it has successfully drawn final candidates for the clinical trials of the next-generation chimeric antigen receptor T (CAR-T) cell therapy for ovarian cancer.

Abclon plans to enter clinical trials in … Read more

New Standard in Recurrent, Platinum-Sensitive Ovarian Cancer

April 21, 2020 10:00 am

By Pam Harrison

Replacing gemcitabine (Gemzar) with pegylated liposomal doxorubicin in a standard platinum-based regimen improved survival in recurrent ovarian cancer, a phase III trial has shown.

In a cohort of nearly 700 women receiving carboplatin plus bevacizumab (Avastin), median … Read more

Gemcitabine–Pazopanib Combo Shows Antitumor Efficacy in Ovarian Cancer

April 17, 2020 11:00 am

Toronto, Canada—Findings from a phase 2 study prepared for presentation at the 2020 SGO Annual Meeting on Women’s Cancer showed that adding pazopanib to gemcitabine enhanced antitumor activity in patients with ovarian cancer.

“Angiogenesis inhibition is a valuable strategy for … Read more

Olaparib Matches Chemotherapy Outcomes in Platinum-Sensitive Recurrent Ovarian Cancer

April 17, 2020 10:30 am

By Lisa Astor

Treatment with olaparib demonstrated similar outcomes to standard-of-care chemotherapy treatment in patients with BRCA wild-type, platinum-sensitive, recurrent epithelial ovarian cancer in the phase II CLIO study. As such, olaparib failed to demonstrate a significant improvement in survival Read more

Drug May Help Overcome Chemo Resistance in Ovarian Cancer

April 17, 2020 10:00 am

Scientists from Mater Research – The University of Queensland, have discovered they can overcome chemotherapy resistance in an ovarian cancer subtype by using low doses of a drug which slows cell growth.

Led by Professor John Hooper, the TRI-based Mater … Read more

New Cancer Drug Shrinks Tumors, Reduces Side Effects, in Animal Studies

April 15, 2020 10:00 am

By Brita Belli

A class of experimental cancer drugs called BET inhibitors have shown promise for treating cancers of the blood, but can induce toxic side effects. Now Yale researchers have found a new inhibitor that in animal studies demonstrates … Read more

Frontline Niraparib Plus Bevacizumab for Advanced Ovarian Cancer Yields Promising Activity

April 13, 2020 12:00 pm

By Gina Columbus

Frontline niraparib in addition to bevacizumab as maintenance demonstrated impressive clinical activity in patients with advanced ovarian cancer who achieved either a complete or partial response to frontline platinum-based chemotherapy with bevacizumab, according to the phase II Read more

Olaparib/Bevacizumab as Frontline Maintenance Improves PFS in Ovarian Cancer, Regardless of Timing of Surgery, Disease Status

April 8, 2020 10:00 am

By Gina Columbus

The combination of olaparib (Lynparza) and bevacizumab (Avastin) was found to improve progression-free survival (PFS) outcomes versus bevacizumab alone as a frontline maintenance treatment in patients with newly diagnosed advanced high-grade serous ovarian cancer, regardless of the … Read more